Mesa Advises Community Oncologists on JAK Inhibitors for Intermediate-Risk Myelofibrosis
Ruben Mesa, MD, director of the Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center, gives advice on using the JAK inhibitors ruxolitinib and fedratinib in the community setting for patients with intermediate-risk myelofibrosis.<br />
Ruben Mesa, MD, director of the Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center, gives advice on using the JAK inhibitors ruxolitinib (Jakafi) and fedratinib (Inrebic) in the community setting for patients with intermediate-risk myelofibrosis.
JAK inhibition is an alternative option and as such, it opens the door to improvements in outcomes. Mesa says this has been seen previously when multiple options became available in CML, MDS, and AML. The majority of patients diagnosed with myelofibrosis are already on therapy. Those patients who have a suboptimal response to their current treatment do not have many second-line options outside of clinical trials. Therefore, having an approved agent like ruxolitinib and fedratinib.
FDA Approves Nilotinib With No Mealtime Restrictions in Ph-Positive CML
November 15th 2024The FDA has approved a re-engineered formulation of nilotinib with no mealtime restrictions for adult patients with newly diagnosed Ph-positive CP- and AP-CML, or for those resistant or intolerant to prior therapy, including imatinib.
Read More
